The Lancet - UCSF News Center - Medscape Medical News - January 26, 2012
In the two largest clinical studies ever conducted on the
molecular genetics of lung cancer, an international team, led
by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D.,
demonstrated that a molecular test
could better predict the likelihood
of recurrence and risk of death in patients who
have undergone surgery for early-stage lung cancer, versus
conventional NCCN staging guidelines. In
comparison to earlier prognostic assays for lung
cancer, this one, according to John Minna,
M.D.", Max L. Thomas Distinguished Chair in
Molecular Pulmonary Oncology at UT Southwestern stands "head
and shoulders" above the rest and is ready for
"prime time" clinical use.
UCSF-Pfizer Collaboration Project to Fast-Track Treatments for Lung Cancer
Thoracic Oncology Program - January 09, 2012
A team consisting of Hassan Lemjabbar-Alaoui,
Ph.D., Assistant Adjunct Professor of Surgery and
principal Investigator in the Thoracic Oncology
Laboratory and Alaoui
Lab, and Steven Rosen, PhD, Professor and Vice-chair of the
Department of Anatomy, are developing a novel
treatment for lung cancer in a unique collaboration
between UCSF and Pfizer, the world's largest drug company. The
Rosen-Alaoui team has identified an enzyme found at high
levels in lung and other cancers and is developing
antibodies to target the enzyme and disable the cancer,
even in cells rendered cancerous by cigarette
smoke.The partnership enables the teams to combine their unique
areas of expertise to push the pace of development, Rosen said.
"That's the whole idea: merge our strengths and speed the process
along, compared to what either party could do alone."
Thoracic Oncology Lab Acquires State-of-the-Art DNA Sequencer
UCSF Thoracic Oncology Program - October 18, 2011
Click Image to
Enlarge
The UCSF Thoracic Oncology
Laboratory recently acquired the 5500 Series SOLiDTM , a
next-generation DNA sequencer manufactured by Life Technologies
Inc. This state-of-the-art sequencer offers a level of
precision previously unattainable, and empowers lab
scientists to more deeply probe the underlying molecular
biology of myriad cancers: from primary thoracic tumors such
as lung cancer, esophageal cancer, and mesothelioma, to
metastatic sarcoma, melanoma, colorectal cancer, and breast
cancer that has spread to the lung.Insights gained
from this research could lead to more effective
treatments, and possibly a cure for these diseases.
The UCSF Thoracic Oncology Program,
led by David M. Jablons, M.D., has been at the forefront of
groundbreaking laboratory and clinical research, and offers expert
and compassionate care through its multidisciplinary team of thoracic
specialists. The Thoracic Oncology Program at UCSF would like to
acknowledge Gordon and Emily Bankhead and the Kazan, McClain,
Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman
Foundation for their generous support.
Thoracic Oncology Program - The Year in Review
Thoracic Oncology Program - August 04, 2011
Every July, the Thoracic Oncology Program
provides a summary update of its accomplishments during the prior
twelve (12) months. The program continues to
grow and innovate.General Thoracic
Surgery continues to innovate and expand the number of
minimally invasive procedures it performs. The program's status as
the busiest on the West Coast and the best place to refer complex
and challenging cases continues. With a strong multidisciplinary team including
UCSF Medical Oncology, Radiation Oncology and Pulmonology, the
program continues to offer state-of-the-art care for the region and
beyond.
The Relationship Between Cancer Evolution & Drug Resistance: The Carlo Maley Interview with Science Cafe
UCSF Science Cafe - January 10, 2011
In a far ranging interview with UCSF reporter Jeffrey Norris, Carlo C. Maley, Ph.D., Associate
Professor of Surgery in the Thoracic Oncology
Program, discussed cancer evolution, drug resistance,
and the development of new treatment strategies. "The
problem of building a multi-cellular organism is really the problem
of suppressing cancer," said Dr. Maley, an expert in both
evolutionary biology and bioinformatics. "How do you get cells to
stop proliferating and to devote their resources to the good of the
larger organism?"
Thoracic Oncology Program Launches Lab Collaboration in China
UCSF Thoracic Oncology Laboratory - October 01, 2010
The UCSF Thoracic Oncology
Laboratory, led by David Jablons, M.D., Professor
and Chief of Thoracic Surgery and Program Leader of Thoracic
Oncology, recently launched its first Lung Cancer
Joint Laboratory in China, an alliance with Guangzhou
Institute of Respiratory Disease (China National Key Laboratory of
Respiratory Disease) and the First Affiliated Hospital of Guangzhou
Medical College. A signing ceremony was held in
Guangzhou, China.
Dr. Carlo C. Maley Joins UCSF Department of Surgery Faculty
Department of Surgery - September 01, 2010
Carlo
C. Maley, Ph.D.has joined the faculty as an Associate
Professor in the Thoracic Oncology Program and Division of
Adult Cardiothoracic Surgery. Dr. Maley is Director of the Maley Lab and is a Principal
Investigator and Collaborator in the Thoracic Oncology Lab. Dr.
Maley is focused on the evolution of cancer, specifically
carcinogenesis, neoplastic progression, and therapeutic
resistance, with the ultimate goal of preventing cancer and
improving current therapies.
Putting Drug Development In Patients' Hands
Wall Street Journal Online - July 29, 2008
"To find answers, Mrs. Addario and her
husband, along with David M.
Jablons, her surgeon from the University of California, San
Francisco, put together a two-day conference last fall of lung
cancer researchers from major institutions around the world.
She says the group identified a number of problems that hinder
progress toward a cure. Among them: Researchers didn't know what
others were doing, tissue and blood specimens needed for
experiments weren't centrally located or shared, and the findings
of experiments weren't integrated to help assess what the key
priorities should be. Mrs. Addario started a new organization, the
Addario Lung Cancer Medical
Institute, and hired CollabRx to address some of these issues.
The company is helping the institute build a virtual specimen bank
where researchers participating in the project can share patient
specimens and establish joint standards for collecting future
specimens."
The UCSF 
